Aurobindo Pharma, a mid-size pharmaceutical company, notified the stock exchanges that it had received an establishment inspection report (EIR) from the US drug regulator (USFDA) for Hyderabad unit.

It said ''the company has received EIR with voluntary action initiated (VAI) status from the United States Food and Drug Administration (USFDA).''

In November, USFDA inspected Unit IV, a general injectable formulation manufacturing facility at Pashamylaram in Hyderabad and had issued 'Form 483' with 14 observations.

Shares of the company gained Rs 102.05, or 20.4%, to settle at Rs 602.25. The total volume of shares traded was 897,415 at the BSE (Wednesday).